Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial

Study limitation reported by the research below: “The external control (Myeloma XI) had a much longer median follow-up (~118 months) vs OPTIMUM (~71 months), which may affect OS comparisons as OPTIMUM OS data are still maturing.”